Oncology and Hematology - Prova Education

Episodes 97-112 of 113

Incorporation of guidelines-concordant immunotherapy in the perioperative setting of NSCLC
Incorporation of guidelines-concordant immunotherapy in the perioperative setting of NSCLC
MinuteCE®
Incorporation of guidelines-concordant immunotherapy in the perioperative setting of NSCLC
1.00 program credit
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credit
Emerging and practice-changing directions in NSCLC within the perioperative and locally advanced settings
Emerging and practice-changing directions in NSCLC within the perioperative and locally advanced settings
MinuteCE®
Emerging and practice-changing directions in NSCLC within the perioperative and locally advanced settings
1.00 program credit
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credit
Insights from global key opinion leaders on optimizing patient care in NSCLC
Insights from global key opinion leaders on optimizing patient care in NSCLC
MinuteCE®
Insights from global key opinion leaders on optimizing patient care in NSCLC
1.00 program credit
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credit
Guidelines-recommended first-line treatment with immunotherapy-based regimens in PD-L1- positive metastatic NSCLC
Guidelines-recommended first-line treatment with immunotherapy-based regimens in PD-L1- positive metastatic NSCLC
MinuteCE®
Guidelines-recommended first-line treatment with immunotherapy-based regimens in PD-L1- positive metastatic NSCLC
1.00 program credit
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credit
Warm Autoimmune Hemolytic Anemia: How Antibody-Based Therapies Are Revolutionizing Its Management
Warm Autoimmune Hemolytic Anemia: How Antibody-Based Therapies Are Revolutionizing Its Management
CME/CE
Warm Autoimmune Hemolytic Anemia: How Antibody-Based Therapies Are Revolutionizing Its Management
0.25 credits
- Caroline Piatek, MD
- Irina Murakhovskaya, MD
0.25 credits
First-Line Treatment of Adults with Classical Hodgkin Lymphoma
First-Line Treatment of Adults with Classical Hodgkin Lymphoma
MinuteCE®
First-Line Treatment of Adults with Classical Hodgkin Lymphoma
1.00 program credit
- Alex Herrera, MD
- Alison J. Moskowitz, MD
1.00 program credit
Patient Selection for ADCs in First-Line DLBCL
Patient Selection for ADCs in First-Line DLBCL
MinuteCE®
Patient Selection for ADCs in First-Line DLBCL
1.00 program credit
- John P. Leonard, MD
- Sarah Rutherford, MD
1.00 program credit
Clinical Implications of Bispecific Antibodies and Antibody-Drug Conjugates in FL
Clinical Implications of Bispecific Antibodies and Antibody-Drug Conjugates in FL
MinuteCE®
Clinical Implications of Bispecific Antibodies and Antibody-Drug Conjugates in FL
1.00 program credit
- Kami Maddocks, MD
- Matthew J. Matasar, MD
1.00 program credit
Late-Stage Bispecifics and ADCs in DLBCL
Late-Stage Bispecifics and ADCs in DLBCL
MinuteCE®
Late-Stage Bispecifics and ADCs in DLBCL
1.00 program credit
- Sarah Rutherford, MD
- John P. Leonard, MD
1.00 program credit
MinuteCE®
Contextualizing the Evidence in Lymphomas: ADCs and Bispecific Antibodies in HL, FL, and DLBCL
1.00 credit 9 episodes
- John P. Leonard, MD
- Matthew J. Matasar, MD
- Alex Herrera, MD
- Kami Maddocks, MD
- Alison J. Moskowitz, MD
- Sarah Rutherford, MD
1.00 credit 9 episodes
Bispecific Antibodies in FL
Bispecific Antibodies in FL
MinuteCE®
Bispecific Antibodies in FL
1.00 program credit
- Kami Maddocks, MD
- Matthew J. Matasar, MD
1.00 program credit
Individualizing Frontline Treatment
Individualizing Frontline Treatment
MinuteCE®
Individualizing Frontline Treatment
1.00 program credit
- Alex Herrera, MD
- Alison J. Moskowitz, MD
1.00 program credit
Antibody-Drug Conjugates in FL
Antibody-Drug Conjugates in FL
MinuteCE®
Antibody-Drug Conjugates in FL
1.00 program credit
- Matthew J. Matasar, MD
- Kami Maddocks, MD
1.00 program credit
Application of Data from the ECHELON-1 Trial
Application of Data from the ECHELON-1 Trial
MinuteCE®
Application of Data from the ECHELON-1 Trial
1.00 program credit
- Alison J. Moskowitz, MD
- Alex Herrera, MD
1.00 program credit
NCCN Guideline Updates in DLBCL
NCCN Guideline Updates in DLBCL
MinuteCE®
NCCN Guideline Updates in DLBCL
1.00 program credit
- John P. Leonard, MD
- Sarah Rutherford, MD
1.00 program credit
Treatment Options for Invasive Fungal Infections: Why They Don't Always Work
Treatment Options for Invasive Fungal Infections: Why They Don't Always Work
CME/CE
Treatment Options for Invasive Fungal Infections: Why They Don't Always Work
- Thomas F. Patterson, MD, FACP, FIDSA
- George Thompson III, MD, FIDSA

7/7